{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:15:51Z","timestamp":1778886951953,"version":"3.51.4"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Detailed epidemiologic descriptions of large populations of advanced stage ovarian cancer patients have been lacking to date. This study aimed to describe the patient characteristics, treatment patterns, survival, and incidence rates of health outcomes of interest (HOI) in a large cohort of advanced stage ovarian cancer patients in the United States (US).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This cohort study identified incident advanced stage (III\/IV) ovarian cancer patients in the US diagnosed from 2010 to 2018 in the HealthCore Integrated Research Database (HIRD) using a validated predictive model algorithm. Descriptive characteristics were presented overall and by treatment line. The incidence rates and 95% confidence intervals for pre-specified HOIs were evaluated after advanced stage diagnosis. Overall survival, time to treatment discontinuation or death (TTD), and time to next treatment or death (TTNT) were defined using treatment information in claims and linkage with the National Death Index.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>We identified 12,659 patients with incident advanced stage ovarian cancer during the study period. Most patients undergoing treatment received platinum agents (75%) and\/or taxanes (70%). The most common HOIs (&gt;\u200924 per 100 person-years) included abdominal pain, nausea and vomiting, anemia, and serious infections. The median overall survival from diagnosis was 4.5\u2009years, while approximately half of the treated cohort had a first-line time to treatment discontinuation or death (TTD) within the first 4 months, and a time to next treatment or death (TTNT) from first to second-line of about 6 months.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study describes commercially insured US patients with advanced stage ovarian cancer from 2010 to 2018, and observed diverse treatment patterns, incidence of numerous HOIs, and limited survival in this population.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13048-020-00691-y","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T21:03:07Z","timestamp":1598907787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["A real-world study on characteristics, treatments and outcomes in US patients with advanced stage ovarian cancer"],"prefix":"10.1186","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2788-3061","authenticated-orcid":false,"given":"Daniel C.","family":"Beachler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francois-Xavier","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devon H.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jade","family":"Dinh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruihua","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aziza","family":"Jamal-Allial","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Dychter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Lanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Verpillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"691_CR1","volume-title":"SEER Cancer statistics review, 1975\u20132016 Bethesda","author":"N Howlader","year":"2019","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Reuer EJ, Cronin KA. SEER Cancer statistics review, 1975\u20132016 Bethesda. MD: National Cancer Institute; 2019. [Based on November 2018 SEER data submission, posted to the SEER web site, April 9]. Available from: https:\/\/seer.cancer.gov\/csr\/1975_2016\/."},{"issue":"5","key":"691_CR2","doi-asserted-by":"publisher","first-page":"798","DOI":"10.3904\/kjim.2017.008","volume":"32","author":"JY Kim","year":"2017","unstructured":"Kim JY, Cho CH, Song HS. Targeted therapy of ovarian cancer including immune check point inhibitor. Korean J Intern Med. 2017;32(5):798\u2013804.","journal-title":"Korean J Intern Med"},{"issue":"1","key":"691_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"30","key":"691_CR4","doi-asserted-by":"publisher","first-page":"3374","DOI":"10.1200\/JCO.2014.55.7348","volume":"32","author":"A du Bois","year":"2014","unstructured":"du Bois A, Floquet A, Kim JW, Rau J, del Campo JM, Friedlander M, et al. Incorporation of pazopanib in maintenance therapy of ovarian cancer. J Clin Oncol. 2014;32(30):3374\u201382.","journal-title":"J Clin Oncol"},{"issue":"33","key":"691_CR5","doi-asserted-by":"publisher","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","volume":"27","author":"UA Matulonis","year":"2009","unstructured":"Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27(33):5601\u20136.","journal-title":"J Clin Oncol"},{"issue":"9698","key":"691_CR6","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009;374(9698):1331\u20138.","journal-title":"Lancet."},{"issue":"3","key":"691_CR7","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1001\/jamaoncol.2018.5953","volume":"5","author":"JM Unger","year":"2019","unstructured":"Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of Patient Comorbid Conditions with Cancer Clinical Trial Participation. JAMA Oncol. 2019;5(3):326\u201333.","journal-title":"JAMA Oncol"},{"issue":"5","key":"691_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1200\/JCO.2012.45.4553","volume":"31","author":"JM Unger","year":"2013","unstructured":"Unger JM, Hershman DL, Albain KS, Moinpour CM, Petersen JA, Burg K, et al. Patient income level and cancer clinical trial participation. J Clin Oncol. 2013;31(5):536\u201342.","journal-title":"J Clin Oncol"},{"key":"691_CR9","doi-asserted-by":"publisher","unstructured":"Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors Associated With Age Disparities Among Cancer Clinical Trial Participants. JAMA Oncol. 2019;5(12). https:\/\/doi.org\/10.1001\/jamaoncol.2019.2055.","DOI":"10.1001\/jamaoncol.2019.2055"},{"issue":"suppl_8","key":"691_CR10","doi-asserted-by":"publisher","first-page":"viii61","DOI":"10.1093\/annonc\/mdx443","volume":"28","author":"EA Eisenhauer","year":"2017","unstructured":"Eisenhauer EA. Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii61\u2013viii5.","journal-title":"Ann Oncol"},{"key":"691_CR11","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canep.2019.05.006","volume":"61","author":"DB Esposito","year":"2019","unstructured":"Esposito DB, Russo L, Oksen D, Yin R, Desai VCA, Lyons JG, et al. Development of predictive models to identify advanced-stage cancer patients in a US healthcare claims database. Cancer Epidemiol. 2019;61:30\u20137.","journal-title":"Cancer Epidemiol"},{"key":"691_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2147\/POR.S140579","volume":"8","author":"DM Kern","year":"2017","unstructured":"Kern DM, Barron JJ, Wu B, Ganetsky A, Willey VJ, Quimbo RA, et al. A validation of clinical data captured from a novel Cancer care quality program directly integrated with administrative claims data. Pragmat Obs Res. 2017;8:149\u201355.","journal-title":"Pragmat Obs Res"},{"issue":"2","key":"691_CR13","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cogc.2013.02.001","volume":"5","author":"SJ Johnson","year":"2012","unstructured":"Johnson SJ, Sorg RA, Borker RD, Duh MS. Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed With Advanced Ovarian Cancer. Clin Ovarian Gynecol Cancer. 2012;5(2):67\u201377.e1.","journal-title":"Clin Ovarian Gynecol Cancer"},{"issue":"12","key":"691_CR14","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","volume":"12","author":"SL Cooke","year":"2011","unstructured":"Cooke SL, Brenton JD. Evolution of platinum resistance in high-grade serous ovarian cancer. Lancet Oncol. 2011;12(12):1169\u201374.","journal-title":"Lancet Oncol"},{"key":"691_CR15","volume-title":"NDI early release pilot program 2019 updated February 8","author":"Statistics CNCfH","year":"2016","unstructured":"Statistics CNCfH. NDI early release pilot program 2019 updated February 8 ,2016. Available from: https:\/\/www.cdc.gov\/nchs\/ndi\/ndi_early_release.htm."},{"key":"691_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.08.847","volume-title":"Estimates of PFS, TTNT PER Treatment Line and their Relationship for Multiple Myeloma Patients","author":"E Vago","year":"2017","unstructured":"Vago E, Liwing J, Pan F, Mehra M, Zheng Y, Nahi H. Estimates of PFS, TTNT PER Treatment Line and their Relationship for Multiple Myeloma Patients. Glasgow: ISPOR EU; 2017."},{"issue":"9318","key":"691_CR17","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359(9318):1686\u20139.","journal-title":"Lancet."},{"issue":"6","key":"691_CR18","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"691_CR19","first-page":"431","volume":"7","author":"O Le Saux","year":"2015","unstructured":"Le Saux O, Taylor A, Chia V, Pillas D, Kaur M, Freyer G. Cross-sectional study on comorbidities and adverse events in patients with advanced and recurrent ovarian cancer in France. Clin Epidemiol. 2015;7:431\u201340.","journal-title":"Clin Epidemiol"},{"issue":"Suppl 5","key":"691_CR20","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1634\/theoncologist.7-suppl_5-11","volume":"7","author":"CJ Dunton","year":"2002","unstructured":"Dunton CJ. Management of treatment-related toxicity in advanced ovarian cancer. Oncologist. 2002;7(Suppl 5):11\u20139.","journal-title":"Oncologist."},{"issue":"52","key":"691_CR21","doi-asserted-by":"publisher","first-page":"8084","DOI":"10.1016\/j.vaccine.2018.10.052","volume":"36","author":"D Esposito","year":"2018","unstructured":"Esposito D, Titievsky L, Beachler DC, Hawes JCL, Isturiz R, Scott DA, et al. Incidence of outcomes relevant to vaccine safety monitoring in a US commercially-insured population. Vaccine. 2018;36(52):8084\u201393.","journal-title":"Vaccine."},{"issue":"2","key":"691_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","volume":"18","author":"P Hari","year":"2018","unstructured":"Hari P, Romanus D, Palumbo A, Luptakova K, Rifkin RM, Tran LM, et al. Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical Care in the United States. Clin Lymphoma Myeloma Leuk. 2018;18(2):152\u201360.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"691_CR23","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1093\/annonc\/mdz060","volume":"30","author":"GM Blumenthal","year":"2019","unstructured":"Blumenthal GM, Gong Y, Kehl K, Mishra-Kalyani P, Goldberg KB, Khozin S, et al. Analysis of time-to-treatment discontinuation of targeted therapy, immunotherapy, and chemotherapy in clinical trials of patients with non-small-cell lung cancer. Ann Oncol. 2019;30(5):830\u20138.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"691_CR24","doi-asserted-by":"publisher","first-page":"9064","DOI":"10.1200\/JCO.2018.36.15_suppl.9064","volume":"20","author":"Y Gong","year":"2018","unstructured":"Gong Y, Kehl KL, Oxnard GR, Khozin S, Mishra-Kalyani PS, Blumenthal GM. Time to treatment discontinuation (TTD) as a pragmatic endpoint in metastatic non-small cell lung cancer (mNSCLC): A pooled analysis of 8 trials. JCO. 2018;20(15_suppl):9064 (36).","journal-title":"JCO"},{"issue":"25","key":"691_CR25","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont CR, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian Cancer. N Engl J Med. 2019;381(25):2391\u2013402.","journal-title":"N Engl J Med"},{"issue":"25","key":"691_CR26","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","volume":"381","author":"I Ray-Coquard","year":"2019","unstructured":"Ray-Coquard I, Pautier P, Pignata S, Perol D, Martin-Gonzalez A, Berger R, et al. Olaparib plus Bevacizumab as first-line maintenance in ovarian Cancer. N Engl J Med. 2019;381(25):2416\u201328.","journal-title":"N Engl J Med"},{"key":"691_CR27","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian Cancer. N Engl J Med. 2019;381:2403\u201315.","journal-title":"N Engl J Med"},{"key":"691_CR28","volume-title":"Suvival by time since diagnosis","author":"SEER Explorer - Ovary","year":"2019","unstructured":"SEER Explorer - Ovary. Suvival by time since diagnosis, vol. 5; 2019. Available from: https:\/\/seer.cancer.gov\/explorer\/application.php."},{"issue":"1","key":"691_CR29","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/oxfordjournals.aje.a115470","volume":"131","author":"CA Boyle","year":"1990","unstructured":"Boyle CA, Decoufle P. National sources of vital status information: extent of coverage and possible selectivity in reporting. Am J Epidemiol. 1990;131(1):160\u20138.","journal-title":"Am J Epidemiol"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-020-00691-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-020-00691-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:59:24Z","timestamp":1630367964000},"score":1,"resource":{"primary":{"URL":"https:\/\/ovarianresearch.biomedcentral.com\/articles\/10.1186\/s13048-020-00691-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["691"],"URL":"https:\/\/doi.org\/10.1186\/s13048-020-00691-y","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the New England Institutional Review Board (Work Order Number 1\u20139472-1). The current study was designed as an analysis based on claims data from a large insured population in the US. There was no active enrollment or active follow-up of study subjects, and no data was collected directly from individuals. The HIPAA Privacy Rule permits PHI in a limited data set to be used or disclosed for research, without individual authorization, if certain criteria are met (further described 45 CFR Part 160 and Subparts A and E of Part 164). Thus informed consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable, as all results presented in this manuscript were aggregated.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DB, DT, JD, AJA, and SL are employees of HealthCore, Inc. (a subsidiary of Anthem Inc.), which received funding from Pfizer Inc. and Merck Healthcare KGaA (Darmstadt, Germany) for this study. FXL and PV are employees of Merck Healthcare KGaA (Darmstadt, Germany) and LR and SD are employees of Pfizer Inc. RY was an employee of HealthCore, Inc. at the time of this study, and is a current employee of Anthem Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"101"}}